Spirulina supplementation and anthropometric indices: A systematic review and meta-analysis of controlled clinical trials.
Meysam ZarezadehAmir Hossein FaghfouriNima RadkhahElaheh ForoumandiMasoud KhorshidiAhmadreza RasouliMahtab ZareiNiyaz Mohammadzadeh HonarvarNazanin Hazhir KarzarMehrangiz Ebrahimi-MameghaniPublished in: Phytotherapy research : PTR (2020)
Obesity and overweight are associated with the burden of chronic diseases. The aim of the present meta-analysis is to determine the efficacy of spirulina in reducing of obesity indices. PubMed, Web of Science, Scopus, EMBASE and Cochrane library databases were searched up to November 2019. Randomized controlled trials comparing spirulina supplementation with a placebo or no treatment for anthropometric indices were included. Meta-analysis was performed using random-effects model. Subgroup analysis and meta-regression were carried out. Publication bias was evaluated using standard methods. Spirulina had ameliorative effects on weight (WMD = -1.85 Kg; 95% CI: -2.44, -1.26; p < .001; I2 = 82.4%, p < .001), and waist circumference (WMD = -1.09 cm; 95% CI: -2.16, -0.01; p = .046; I2 = 0.0%, p = .757) while no significant effect was shown on body mass index, even after sensitivity analysis (SMD = -0.53 Kg/m2 ; 95% CI: -1.25, 0.19; p = .149; I2 = 92.9%, p < .001); however, spirulina was effective in studies lasted for at least 12 weeks (SMD = -1.25 Kg/m2 ; 95% CI: -2.21, -0.28; p = .011; I2 = 90.8%, p < .001). Spirulina supplementation exerts beneficial effects on weight and waist circumference. The ameliorative effect of spirulina on body mass index was revealed in longer duration of supplementation.
Keyphrases
- body mass index
- weight gain
- systematic review
- weight loss
- physical activity
- clinical trial
- randomized controlled trial
- meta analyses
- metabolic syndrome
- insulin resistance
- type diabetes
- case control
- public health
- body composition
- body weight
- risk factors
- skeletal muscle
- deep learning
- machine learning
- high fat diet induced
- open label
- phase iii
- combination therapy